Ozempic & GLP-1 Drug Lawsuit
Ozempic, Wegovy, and other GLP-1 receptor agonist drugs have been linked to severe gastrointestinal injuries including gastroparesis (stomach paralysis), bowel obstruction, and pancreatitis. Lawsuits are being filed against Novo Nordisk and Eli Lilly.
Defendant: Novo Nordisk, Eli Lilly | MDL 3094 — Eastern District of Pennsylvania. Rapidly growing docket.
Key Facts
Who Qualifies
Individuals who used Ozempic, Wegovy, Rybelsus, Mounjaro, or Trulicity and suffered serious gastrointestinal injuries or other severe side effects.
Related Injuries
- Gastroparesis (stomach paralysis)
- Intestinal obstruction / bowel blockage
- Pancreatitis
- Gallbladder disease
- Kidney injury
- Severe nausea and vomiting requiring hospitalization
Settlement Status
No settlements have been reached yet. Cases are in active litigation within the MDL.
Learn More About This Lawsuit
Ozempic Lawsuit Overview
Everything you need to know about the Ozempic and GLP-1 drug lawsuit — gastroparesis, bowel obstruction, and other severe side effects linked to semaglutide medications.
Do I Qualify for the Ozempic Lawsuit?
Find out if you meet the criteria to file an Ozempic or GLP-1 drug lawsuit. Eligibility requirements and free case evaluation.
Ozempic Lawsuit Settlement Amounts — April 2026 Update
Latest information on Ozempic lawsuit settlement amounts, expected timelines, and what similar pharmaceutical cases have paid.
Ozempic Lawsuit FAQ
Frequently asked questions about the Ozempic and GLP-1 drug lawsuit — eligibility, costs, timeline, and what to expect.
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.
This website is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by using this site or submitting a contact form. Prior results do not guarantee a similar outcome.
Free Case Review
Find out if you may qualify for compensation. No cost, no obligation.
ATTORNEY ADVERTISING. This website may be considered attorney advertising in some jurisdictions.